Accession Number: | 0001209191-22-037027 |
Date: | 2022-06-13 |
Issuer: | KINNATE BIOPHARMA INC. (KNTE) |
Original Submission Date: |
FLAHERTY KEITH T.
103 MONTGOMERY STREET, SUITE 150
THE PRESIDIO OF SAN FRANCISCO
SAN FRANCISCO, CA 94129
Title of Security | Transaction Date | 2a. Deemed Execution Date | Transaction Code | Shares | Acquired or Disposed | Price per share | 5. Amount of Securities Beneficially Owned Following Reported Transaction | 6. Ownership Form Direct or Indirect | Nature of Indirect Ownership |
---|
Title of Derivative Security | Conversion or Exercise Price of Derivative Security | Transaction Date | Deemed Execution Date | Transaction Code | Number of Derivative Securities Acquired (A) or Disposed of (D) | Date Exercisable | Expiration Date | Title and Amount of Securities Underlying Derivative Security | Price of Derivative Security | Number of derivative Securities Beneficially Owned Following Reported Transaction(s) | Ownership Form: Direct (D) or Indirect (I) | Nature of Indirect Beneficial Ownership |
---|---|---|---|---|---|---|---|---|---|---|---|---|
STOCK OPTION (RIGHT TO BUY) | 8.38 | 2022-06-13 | deemed execution date | A | 20,250 (a) | 2032-06-13 | common stock 20,250 | $8.38 | 20,250 | direct |
ID | footnote |
---|---|
f1 | 1/12th of the shares underlying the option vest and become exercisable on a monthly basis starting july 13, 2022 (the vest base date) and thereafter on the same day of the month as the vest base date or if earlier, the day immediately before the date of the next annual meeting of stockholders that occurs after the vest base date. |